Funded Startups in Hayward
Across 26 Hayward-based rounds shown here, the largest disclosed amount is Eikon Therapeutics’ $351M (2025-02-26), dwarfing the next-largest disclosed roun…
Across 26 Hayward-based rounds shown here, the largest disclosed amount is Eikon Therapeutics’ $351M (2025-02-26), dwarfing the next-largest disclosed rounds of $150M (Arcus Biosciences, 2025-02-18) and $105M (RefleXion Medical, 2023-11-15). Several other biotech-heavy financings cluster in the same mid-February 2025 window (Arcus on 2025-02-18 and Eikon on 2025-02-26), while the largest non-biotech tickets still sit below the $80M mark (Blue Current at $80M on 2025-12-08; Halio at $70M on 2023-11-16). The table also shows a persistent biotech presence: Biotechnology appears in 8 of 26 entries, more than any other sector. Stage classification is frequently unspecified, with 18 entries marked “Series Unknown” and two additional entries carrying “undisclosed” amounts (Endiatx on 2024-12-01; YO-KAI EXPRESS on 2022-09-01). Chronologically, the rounds span 2021-08-01 (Renovai, $3M) through 2026-05-29 (Potrero Medical, $7M).
Most recent rounds
26 shownRelated listings
Frequently asked
What stands out most in round size, and does it look like a single outlier or a broader high-end cluster?
Eikon Therapeutics’ $351M (2025-02-26) is the only disclosed round here above $150M, and it sits far above the next tier: $150M (Arcus Biosciences, 2025-02-18) and $105M (RefleXion Medical, 2023-11-15). The rest of the disclosed amounts are comparatively concentrated below that top bracket, with multiple mid-size deals in the $60M–$85M range (e.g., Moximed $61M on 2024-08-13; Blue Current $80M on 2025-12-08; CymaBay Therapeutics $85M on 2023-01-24).
Are there noticeable time-window clusters among these Hayward rounds?
Yes: two of the largest disclosed biotech rounds land eight days apart in February 2025—Arcus Biosciences at $150M on 2025-02-18 and Eikon Therapeutics at $351M on 2025-02-26. More broadly, the dataset’s recent edge runs tightly from 2025-02-18 through 2026-05-29, with the most recent entry being Potrero Medical at $7M on 2026-05-29.
Which sectors appear most often, and does biotech dominate the list by volume?
Biotechnology appears in 8 of 26 entries, including large disclosed rounds like Eikon Therapeutics ($351M, 2025-02-26), Arcus Biosciences ($150M, 2025-02-18), and CymaBay Therapeutics ($85M, 2023-01-24). The next-most frequent sectors are much smaller in count (e.g., Artificial Intelligence (AI) appears in 4 entries: Potrero Medical 2026-05-29 $7M; Aqtual 2025-07-10 $31M; Ripcord 2024-04-16 $32M; Renovai 2021-08-01 $3M).
How complete is the stage data, and how often do the listings omit amount or stage?
Stage labeling is frequently missing: 18 of 26 rows are marked “Series Unknown” (including Potrero Medical on 2026-05-29 with $7M and Quartzy on 2026-04-13 with $23M). Additionally, 2 rows have “undisclosed” amounts (Endiatx on 2024-12-01; YO-KAI EXPRESS on 2022-09-01), which limits comparisons for those financings’ size.
What are the extremes in disclosed amounts, and are the smallest rounds concentrated in a particular sector?
The smallest disclosed amount shown is CHawk Technology Int'l’s $100K (2021-10-06), marked as Private Equity. The next-smallest disclosed amounts are $1M for multiple entries (Frontier Bio 2024-12-25; Horizon Treatment Services 2024-03-14; Microvi Biotechnologies 2022-11-15), spanning Biotechnology (Frontier Bio, Microvi Biotechnologies) and Health Care (Horizon Treatment Services).
Which entries closed most recently, and do recent deals skew toward any sector or stage?
The most recent date in the list is 2026-05-29 (Potrero Medical, $7M, Series Unknown), followed by 2026-05-12 (Pulse Biosciences, $13M, Series Unknown) and 2026-04-13 (Quartzy, $23M, Series Unknown). In this latest window, the stage classification is consistently “Series Unknown,” while sectors vary across AI (Potrero Medical), Health Care (Pulse Biosciences), and Commerce and Shopping (Quartzy).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.